MiRAVA Therapeutics is developing miRHeal Pro, an advanced wound care solution aimed at healing chronic, non-healing ulcers. miRHeal Pro leverages cutting-edge microRNA technology to promote vascularisation and accelerate wound healing. By directly targeting key molecular pathways that hinder wound repair, it offers a novel approach to restoring tissue health and addressing chronic ulcers effectively. Our mission is to drive innovation in healthcare by creating therapies that improve patient outcomes, enhance quality of life, and help reduce the financial burden on healthcare systems.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Edinburgh, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Biotechnology, Gene Therapy, Wound Healing.
- HQ
- Edinburgh
Mirava Therapeutics Questions
Mirava Therapeutics's website is https://www.miravatherapeutics.com/
Mirava Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/mirava-therapeutics
Mirava Therapeutics has
1 employees.
View email and phone details for 1
employees at Mirava Therapeutics.
Mirava Therapeutics's industry is
Biotechnology Research
Mirava Therapeutics's top competitors are
Askbio Inc.,
Eulysis Uk Ltd (Acq. In 2016),
Medannex Ltd,
Panazee,
Midlothian Science Zone,
Sarawak Infectious Disease Centre (Sidc).
Mirava Therapeutics's categories are Biotechnology Research
Mirava Therapeutics's founding year is 2023
